Literature DB >> 24464422

Vaccine therapies for chronic hepatitis B: can we go further?

Yumei Wen1, Xuanyi Wang, Bin Wang, Zhenhong Yuan.   

Abstract

Chronic hepatitis B is a major health burden worldwide. In addition to the recent progress in antiviral treatment, therapeutic vaccination is a promising new strategy for the control of chronic hepatitis B. On the basis of the major specific and non-specific immune dysregulations and defects in chronic hepatitis B patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-based therapeutic vaccines, which have undergone clinical trials. The advantages, disadvantages, and future perspectives for these therapeutic vaccines are discussed.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24464422     DOI： 10.1007/s11684-014-0313-7

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  44 in total

1.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 2.  Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections.

Authors:  Yu-mei Wen
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

3.  Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy.

Authors:  Y M Wen; X H Wu; D C Hu; Q P Zhang; S Q Guo
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

4.  Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies.

Authors:  E Celis; V R Zurawski; T W Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

5.  Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers.

Authors:  Jin Luo; Jun Li; Rui L Chen; Lei Nie; Jie Huang; Zheng W Liu; Lin Luo; Xiao J Yan
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

6.  A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.

Authors:  J Heathcote; J McHutchison; S Lee; M Tong; K Benner; G Minuk; T Wright; J Fikes; B Livingston; A Sette; R Chestnut
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

7.  Early kinetics of innate and adaptive immune responses during hepatitis B virus infection.

Authors:  P Fisicaro; C Valdatta; C Boni; M Massari; C Mori; A Zerbini; A Orlandini; L Sacchelli; G Missale; C Ferrari
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059

8.  Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

Authors:  Dao-Zhen Xu; Xuan-Yi Wang; Xin-Liang Shen; Guo-Zhong Gong; Hong Ren; Li-Min Guo; Ai-Min Sun; Min Xu; Lan-Juan Li; Xin-Hui Guo; Zhen Zhen; Hui-Fen Wang; Huan-Yu Gong; Cheng Xu; Nan Jiang; Chen Pan; Zuo-Jiong Gong; Ji-Ming Zhang; Jia Shang; Jie Xu; Qing Xie; Tie-Feng Wu; Wen-Xiang Huang; Yong-Guo Li; Jing Xu; Zheng-Hong Yuan; Bin Wang; Kai Zhao; Yu-Mei Wen
Journal:  J Hepatol       Date:  2013-05-11       Impact factor: 25.083

9.  PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.

Authors:  Guoping Peng; Shuping Li; Wei Wu; Xufei Tan; Yiqiong Chen; Zhi Chen
Journal:  Mol Immunol       Date:  2007-09-14       Impact factor: 4.407

10.  A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.

Authors:  Dao-Zhen Xu; Kai Zhao; Li-Min Guo; Lan-Juan Li; Qing Xie; Hong Ren; Ji-Ming Zhang; Min Xu; Hui-Fen Wang; Wen-Xiang Huang; Wen-Xiang Wang; Xue-Fan Bai; Jun-Qi Niu; Pei Liu; Xin-Yue Chen; Xin-Liang Shen; Zheng-Hong Yuan; Xuan-Yi Wang; Yu-Mei Wen
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240
View more
  4 in total

1.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

Review 2.  Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.

Authors:  Daniel Shouval; Hedwig Roggendorf; Michael Roggendorf
Journal:  Med Microbiol Immunol       Date:  2015-01-04       Impact factor: 3.402

Review 3.  Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Majid Ghayour-Mobarhan; Zahra Meshkat
Journal:  Iran J Basic Med Sci       Date:  2016-07       Impact factor: 2.699

Review 4.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.